National Institute of Biomedical Imaging and Bioengineering; Notice of Meeting, 23600-23601 [2024-07112]
Download as PDF
ddrumheller on DSK120RN23PROD with NOTICES1
23600
Federal Register / Vol. 89, No. 66 / Thursday, April 4, 2024 / Notices
2024–D–0706 for ‘‘New Dietary
Ingredient Notification Master Files for
Dietary Supplements.’’ Received
comments will be placed in the docket
and, except for those submitted as
‘‘Confidential Submissions,’’ publicly
viewable at https://www.regulations.gov
or at the Dockets Management Staff
between 9 a.m. and 4 p.m., Monday
through Friday, 240–402–7500.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ We
will review this copy, including the
claimed confidential information, in our
consideration of comments. The second
copy, which will have the claimed
confidential information redacted/
blacked out, will be available for public
viewing and posted on https://
www.regulations.gov. Submit both
copies to the Dockets Management Staff.
If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://
www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240–402–7500.
You may submit comments on any
guidance at any time (see 21 CFR
10.115(g)(5)).
Submit written requests for single
copies of the draft guidance to the Office
of Dietary Supplement Programs, Center
for Food Safety and Applied Nutrition,
Food and Drug Administration, 5001
Campus Dr., College Park, MD 20740.
Send two self-addressed adhesive labels
to assist that office in processing your
request. See the SUPPLEMENTARY
VerDate Sep<11>2014
17:01 Apr 03, 2024
Jkt 262001
INFORMATION section for electronic
access to the draft guidance.
Lisa
Bieniek, Office of Dietary Supplement
Programs (HFS–810), Center for Food
Safety and Applied Nutrition, Food and
Drug Administration, 5001 Campus Dr.,
College Park, MD 20740, 240–402–2371;
or Lauren Kleinman, Office of
Regulations and Policy (HFS–024),
Center for Food Safety and Applied
Nutrition, Food and Drug
Administration, 5001 Campus Dr.,
College Park, MD 20740, 240–402–2378.
SUPPLEMENTARY INFORMATION:
FOR FURTHER INFORMATION CONTACT:
I. Background
FDA is announcing the availability of
a draft guidance for industry titled,
‘‘New Dietary Ingredient Notification
Master Files for Dietary Supplements.’’
We are issuing the draft guidance
consistent with our good guidance
practices regulation (21 CFR 10.115).
The draft guidance, when finalized, will
represent the current thinking of FDA
on this topic. It does not establish any
rights for any person and is not binding
on FDA or the public. You can use an
alternate approach if it satisfies the
requirements of the applicable statutes
and regulations.
The draft guidance, when finalized,
will provide recommendations to
industry on Master Files for new dietary
ingredient notifications (NDINs). For
purposes of the guidance, a new dietary
ingredient notification Master File
(NDIN Master File or Master File) is a
file containing identity, manufacturing,
and/or safety information relating to a
new dietary ingredient (NDI) that the
Master File owner submits to FDA for
use in evaluating a potential future
NDIN by the Master File owner or by
another person designated by the Master
File owner (e.g., business partner,
supplement manufacturer). An NDIN
Master File contains information about
an NDI, a dietary supplement containing
an NDI, or both. The Master File owner
may refer to the Master File in an NDIN
or may grant written authorization to
other parties to incorporate information
from the Master File by reference in
NDINs. A written authorization granting
a right of reference to a Master File in
an NDIN does not include the right to
see or copy the Master File.
The recommendations in this draft
guidance expand upon and replace the
recommendations related to Master
Files in FDA’s revised draft guidance,
‘‘Dietary Supplements: New Dietary
Ingredient Notifications and Related
Issues,’’ dated August 2016. The
purpose of this draft guidance, when
finalized, will be to help industry
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
comply more easily with the NDIN
requirement in the Federal Food, Drug,
and Cosmetic Act (FD&C Act) by
providing recommendations for the
submission and use of NDIN Master
Files (see section 413(a)(2) of the FD&C
Act (21 U.S.C. 350b(a)(2))). The draft
guidance contains information on
establishing an NDIN Master File,
updating or closing an NDIN Master
File, the use of data from an NDIN
Master File by the Master File owner
and other parties authorized by the
Master File owner, and FDA’s role in
reviewing and administering NDIN
Master Files. Master Files benefit NDIN
submitters with a right of reference by
allowing them to refer to data already on
file with FDA, instead of having to
develop the data themselves and
resubmit it in each NDIN for the same
ingredient.
II. Paperwork Reduction Act of 1995
While this guidance contains no
collection of information, it does refer to
previously approved FDA collections of
information. The previously approved
collections of information are subject to
review by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995 (PRA) (44 U.S.C.
3501–3521). The collection of
information in 21 CFR 190.6 has been
approved under OMB control number
0910–0330, and the collections of
information in 21 CFR part 111 have
been approved under OMB control
number 0910–0606.
III. Electronic Access
Persons with access to the internet
may obtain the draft guidance at either
https://www.fda.gov/regulatoryinformation/search-fda-guidancedocuments or https://
www.regulations.gov. Use the FDA
website listed in the previous sentence
to find the most current version of the
guidance.
Dated: March 28, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024–07095 Filed 4–3–24; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
E:\FR\FM\04APN1.SGM
04APN1
Federal Register / Vol. 89, No. 66 / Thursday, April 4, 2024 / Notices
ddrumheller on DSK120RN23PROD with NOTICES1
meeting of the National Advisory
Council for Biomedical Imaging and
Bioengineering.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council for Biomedical Imaging and
Bioengineering (NACBIB).
Date: May 15, 2024.
Open: 09:00 a.m. to 12:30 p.m.
Agenda: Report from the Institute Director,
Council Members and other Institute Staff.
Place: John Edward Porter Neuroscience
Research Center, Building 35A, Room 620/
630, 35 Convent Drive, Bethesda, Maryland
20892 (In-person Meeting).
Closed: 1:30 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: John Edward Porter Neuroscience
Research Center, Building 35A, Room 620/
630, 35 Convent Drive, Bethesda, Maryland
20892 (In-person Meeting).
Contact Person: David T. George, Ph.D.,
Associate Director for Research
Administration, Office of Research
Administration, National Institute of
Biomedical Imaging and Bioengineering,
6707 Democracy Boulevard, Bethesda, MD
20892, georged@mail.nih.gov.
The meeting will be open to the public,
with attendance limited to space available.
Individuals who plan to attend and need
special assistance, such as sign language
interpretation or other reasonable
accommodations, should notify the Contact
Person listed below in advance of the
meeting. In person attendees should register
at (https://www.nibib.nih.gov/about-nibib/
advisory-council) in advance of the meeting
so that the meeting organizers can plan
accordingly.
The meeting will be videocast and can be
accessed from the NIH Videocasting website
at (https://videocast.nih.gov/watch=54286).
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: https://
www.nibib.nih.gov/about-nibib/advisorycouncil where an agenda and any additional
information for the meeting will be posted
when available.
VerDate Sep<11>2014
17:01 Apr 03, 2024
Jkt 262001
Dated: March 29, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HOMELAND
SECURITY
[FR Doc. 2024–07112 Filed 4–3–24; 8:45 am]
[Docket No. USCG–2024–0232]
23601
Coast Guard
BILLING CODE 4140–01–P
National Maritime Security Advisory
Committee; May 2024 Virtual Meeting
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Diabetes and
Digestive and Kidney Diseases Advisory
Council.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; RFA–DK–22–028
Pilot and Feasibility Trials on the Integration
of Social and Medical Care for T1D.
Date: June 7, 2024.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
NIDDK, Democracy II, Suite 7000A, 6707
Democracy Boulevard, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Cheryl Nordstrom, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7013, 6707 Democracy Blvd.,
Bethesda, MD 20892–2542, 301–402–6711,
cheryl.nordstrom@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: April 1, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–07156 Filed 4–3–24; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
U.S. Coast Guard, Department
of Homeland Security.
ACTION: Notice of open Federal advisory
committee meeting.
AGENCY:
The National Maritime
Security Advisory Committee
(Committee) will conduct a virtual
meeting to discuss a new Committee
task to provide Comment on the U.S.
Coast Guard’s Notice of Proposed
Rulemaking on Cybersecurity in the
Marine Transportation System. The
virtual meeting will be open to the
public.
SUMMARY:
DATES:
Meeting: The Committee will meet
virtually on Friday, May 10, 2024, from
1 p.m. until 3 p.m. Eastern Daylight
Time (EDT). Please note that this
meeting may close early if the
Committee has completed its business.
Comments and supporting
documentation: To ensure your
comments are received by Committee
members before the meeting, submit
your written comments no later than
May 9, 2024.
ADDRESSES: The meeting will be held
virtually. To join the virtual meeting or
to request special accommodations,
contact the individual listed in the FOR
FURTHER INFORMATION CONTACT section
no later than 1 p.m. EDT on May 9,
2024, to obtain the needed information.
The number of virtual lines are limited
and will be available on a first-come,
first-served basis.
Pre-registration information: Preregistration is required for attending
virtual meeting. You must request
attendance by contacting the individual
listed in the FOR FURTHER INFORMATION
CONTACT section of this notice. You will
receive a response with attendance
instructions.
The National Maritime Security
Advisory Committee is committed to
ensuring all participants have equal
access regardless of disability status. If
you require reasonable accommodations
due to a disability to fully participate,
please email Mr. Ryan Owens at
ryan.f.owens.uscg.mil or call (202) 302–
6565 as soon as possible.
Instructions: You are free to submit
comments at any time, including orally
at the meetings as time permits, but if
you want Committee members to review
E:\FR\FM\04APN1.SGM
04APN1
Agencies
[Federal Register Volume 89, Number 66 (Thursday, April 4, 2024)]
[Notices]
[Pages 23600-23601]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-07112]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical Imaging and Bioengineering;
Notice of Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of a
[[Page 23601]]
meeting of the National Advisory Council for Biomedical Imaging and
Bioengineering.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Advisory Council for Biomedical
Imaging and Bioengineering (NACBIB).
Date: May 15, 2024.
Open: 09:00 a.m. to 12:30 p.m.
Agenda: Report from the Institute Director, Council Members and
other Institute Staff.
Place: John Edward Porter Neuroscience Research Center, Building
35A, Room 620/630, 35 Convent Drive, Bethesda, Maryland 20892 (In-
person Meeting).
Closed: 1:30 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications and/or
proposals.
Place: John Edward Porter Neuroscience Research Center, Building
35A, Room 620/630, 35 Convent Drive, Bethesda, Maryland 20892 (In-
person Meeting).
Contact Person: David T. George, Ph.D., Associate Director for
Research Administration, Office of Research Administration, National
Institute of Biomedical Imaging and Bioengineering, 6707 Democracy
Boulevard, Bethesda, MD 20892, [email protected].
The meeting will be open to the public, with attendance limited
to space available. Individuals who plan to attend and need special
assistance, such as sign language interpretation or other reasonable
accommodations, should notify the Contact Person listed below in
advance of the meeting. In person attendees should register at
(https://www.nibib.nih.gov/about-nibib/advisory-council) in advance
of the meeting so that the meeting organizers can plan accordingly.
The meeting will be videocast and can be accessed from the NIH
Videocasting website at (https://videocast.nih.gov/watch=54286).
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
Information is also available on the Institute's/Center's home
page: https://www.nibib.nih.gov/about-nibib/advisory-council where
an agenda and any additional information for the meeting will be
posted when available.
Dated: March 29, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-07112 Filed 4-3-24; 8:45 am]
BILLING CODE 4140-01-P